Both compounds independently cause nausea, vomiting, diarrhea, and constipation - especially during dose increases
Pull back the plunger to the 2mL mark, drawing 2mL of air into the syringe
10.1007/s00125-021-05590-5 Summary Keywords sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, renal outcome, combination therapy, preceding drug, diabetic kidney disease Citation Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Tamura K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Takashi Y and Kawanami D (2024) Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study
Improvements in fibrosis were observed in up to 55% of patients, although these results did not consistently reach statistical significance
doi: 10.1523/JNEUROSCI.23-07-02939.2003
